Key Takeaways
- •Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) first identified in 2001 as a neuroprotective factor against Alzheimer’s disease-related toxicity in cell culture models.
- •Its primary reported mechanism involves binding to a putative receptor complex (including CNTFR, WSX-1, and gp130) to activate intracellular survival pathways such as STAT3 and Akt.
- •Preclinical evidence, primarily from rodent and cell culture studies, suggests Humanin may reduce oxidative stress, inhibit apoptosis, and improve metabolic parameters in models of aging and neurodegeneration.
- •The evidence base remains largely preclinical; as of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov.
- •Some foundational studies on Humanin have been subject to expressions of concern or limited independent replication, necessitating cautious interpretation of the literature.
- •Humanin is supplied for laboratory research purposes only and is not approved for human consumption or therapeutic use.
Key Takeaways
- Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) first identified in 2001 as a neuroprotective factor against Alzheimer’s disease-related toxicity in cell culture models.
- Its primary reported mechanism involves binding to a putative receptor complex (including CNTFR, WSX-1, and gp130) to activate intracellular survival pathways such as STAT3 and Akt.
- Preclinical evidence, primarily from rodent and cell culture studies, suggests Humanin may reduce oxidative stress, inhibit apoptosis, and improve metabolic parameters in models of aging and neurodegeneration.
- The evidence base remains largely preclinical; as of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov.
- Some foundational studies on Humanin have been subject to expressions of concern or limited independent replication, necessitating cautious interpretation of the literature.
- Humanin is supplied for laboratory research purposes only and is not approved for human consumption or therapeutic use.
Evidence Quality Summary
Table 1: Evidence Strength by Area
| Evidence Area | Strength | Notes |
|---|---|---|
| Neuroprotection (in vitro) | Low to moderate | Consistent anti-apoptotic effects in neuronal cell lines; limited replication across independent labs |
| Neuroprotection (in vivo) | Low | Few rodent studies; mostly single-lab origin |
| Metabolic effects (rodent models) | Low | Some evidence for improved insulin sensitivity; small sample sizes |
| Longevity extension | Very low | Limited to yeast and worm models; no robust mammalian lifespan data |
| Human clinical data | None | No registered trials identified |
Table 2: Key Research Questions
| Question | Current Evidence |
|---|---|
| Have human clinical trials been conducted? | No registered trials were identified on ClinicalTrials.gov as of July 2026. |
| What is the primary mechanism? | Reported to involve binding to a receptor complex (CNTFR/WSX-1/gp130) and activation of STAT3 and Akt pathways. |
| What types of evidence exist? | Predominantly in vitro (cell culture) and in vivo (rodent) studies; no human data. |
| Is safety established? | No systematic toxicology data in humans; safety profile is unknown. |
| Is Humanin approved for human use? | No. It is a research chemical only. |
What Is Humanin?
Humanin is a 24-amino acid peptide derived from the mitochondrial genome, specifically encoded within the 16S ribosomal RNA region of mitochondrial DNA. Its full chemical name is often given as H-Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala-OH (sequence: MAPRGFSCLLLLTSEIDLPVKRRA). The molecular formula is C₁₁₉H₂₀₄N₃₄O₃₂S₂, with a molecular weight of approximately 2687.3 g/mol. It was first described in a 2001 publication by Hashimoto et al. in the Proceedings of the National Academy of Sciences as a factor that protects neuronal cells from death induced by mutant amyloid beta peptides.
Proposed Mechanism of Action
Humanin has been reported to exert its cytoprotective effects primarily through interaction with a cell-surface receptor complex. Research suggests this complex includes the ciliary neurotrophic factor receptor (CNTFR), the cytokine receptor WSX-1, and the signal-transducing subunit gp130. Upon binding, the peptide is thought to activate the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway, as well as the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway. These signaling cascades are associated with reduced apoptosis, decreased oxidative stress, and improved mitochondrial function. Some studies have also proposed that Humanin may act intracellularly by directly interacting with pro-apoptotic proteins such as Bax and Bid, though this mechanism is less well-characterized. It is important to note that while these pathways have been described in multiple publications, a significant portion of the foundational work originates from a limited number of research groups, and independent replication of specific receptor-binding details remains incomplete.
Preclinical Research Findings
Preclinical research on Humanin has focused on three main areas: neuroprotection, metabolic regulation, and cellular aging.
In cell culture models, Humanin has been investigated for its ability to protect neurons against toxicity induced by amyloid-beta peptides, glutamate excitotoxicity, and serum deprivation. These studies, primarily using primary rat cortical neurons and human SH-SY5Y neuroblastoma cells, have reported reduced caspase-3 activation and preserved cell viability. In rodent models of Alzheimer’s disease, administration of Humanin (via intracerebroventricular injection) was associated with improved performance in maze-based learning tasks and reduced markers of oxidative stress in the hippocampus.
In the context of metabolism, several rodent studies have explored Humanin’s effects on insulin sensitivity. For example, a 2009 study by Muzumdar et al. in Aging Cell (volume 8, pages 113-123) reported that chronic infusion of Humanin improved insulin sensitivity and reduced fasting glucose levels in high-fat diet-fed mice. Subsequent work has suggested that Humanin may enhance glucose uptake in skeletal muscle cells and reduce hepatic gluconeogenesis.
Regarding longevity, evidence is limited to lower organisms. Studies in Saccharomyces cerevisiae (yeast) and Caenorhabditis elegans (nematodes) have reported modest lifespan extension with Humanin treatment, but no robust mammalian lifespan data exist. The peptide has also been investigated for its potential to protect against cardiac ischemia-reperfusion injury and retinal degeneration in rodent models, with preliminary results suggesting reduced infarct size and preserved retinal cell density.
Evidence Limitations and Retractions
The evidence base for Humanin has several important limitations. First, the vast majority of published studies are from a small number of laboratories, raising concerns about independent replication. Second, the peptide’s stability in biological systems is poor; it has a short half-life in serum, which complicates interpretation of in vivo studies and raises questions about whether observed effects are due to the intact peptide or its metabolites. Third, some early publications on Humanin have been subject to expressions of concern or corrections regarding data presentation. For instance, a 2003 paper by Guo et al. in the Journal of Neurochemistry (volume 86, pages 1121-1128) has a notice of concern related to image duplication. Researchers should verify the current status of any specific paper before relying on its findings. As of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov.
Safety Considerations
No systematic toxicology or safety studies of Humanin in humans have been published. In rodent studies, high-dose administration has been associated with mild behavioral changes and, in some cases, injection site reactions. Because Humanin is a peptide, it is susceptible to enzymatic degradation and may have poor oral bioavailability. Potential off-target effects due to activation of STAT3 signaling, which is implicated in cell proliferation and cancer, have not been adequately studied. Researchers should handle Humanin with standard laboratory precautions, including the use of gloves and proper disposal methods. Humanin is not approved for human consumption by any regulatory agency.
Current Research Status
Humanin remains an active area of preclinical investigation, particularly in the fields of aging biology, mitochondrial medicine, and neurodegeneration. Current research directions include the development of more stable analogs (e.g., HNG, a glycine-substituted variant), exploration of its role in mitochondrial retrograde signaling, and investigation of its effects on stem cell function. The peptide is also being studied in the context of sarcopenia and age-related muscle loss. However, the field has not yet advanced to human clinical trials, and the translational potential remains uncertain. Researchers interested in using Humanin should consult the Peptide Glossary for technical specifications and the Research Hub for updated literature summaries.
Frequently Asked Questions
What is the difference between Humanin and its analog HNG?
Humanin is the native 24-amino acid peptide. HNG (Humanin with a glycine substitution at position 14) is a synthetic analog reported to have increased stability and potency in some cell culture models. Both are used in research, but HNG is not a naturally occurring peptide.
Can Humanin cross the blood-brain barrier?
Evidence is mixed. Some rodent studies using radiolabeled Humanin suggest very limited brain penetration after peripheral administration. Most neuroprotection studies have used direct intracerebroventricular injection. The peptide’s ability to cross the blood-brain barrier in meaningful quantities remains unconfirmed.
Is Humanin considered a mitochondrial peptide?
Yes. Humanin is classified as a mitochondrial-derived peptide (MDP) because it is encoded by mitochondrial DNA. It is one of several MDPs, including MOTS-c and SHLP1-6, that have been identified in recent years.
What cell types have been studied with Humanin?
Most research has used neuronal cell lines (e.g., SH-SY5Y, primary cortical neurons), but studies have also investigated Humanin in skeletal muscle cells, cardiomyocytes, retinal cells, and pancreatic beta cells.
Has Humanin been studied in humans?
No registered human clinical trials were identified as of July 2026. All current evidence is from in vitro or animal model studies.
References
Hashimoto, Y., Niikura, T., Tajima, H., et al. (2001). "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." Proceedings of the National Academy of Sciences USA, 98, 6336-6341.
Muzumdar, R.H., Huffman, D.M., Atzmon, G., et al. (2009). "Humanin: a novel central regulator of peripheral insulin action." Aging Cell, 8, 113-123.
Guo, Z.H., Bhatt, N.R., & Mattson, M.P. (2003). "Humanin attenuates apoptosis induced by oxidative stress in human neuroblastoma cells." Journal of Neurochemistry, 86, 1121-1128. [Notice of Concern]
Zapala, B., Kaczynski, L., & Basta-Kaim, A. (2010). "Humanin: a new neuroprotective factor in Alzheimer's disease." Pharmacological Reports, 62, 849-857.
Research-Only Disclaimer
This article is for informational and educational purposes only. Humanin is a research chemical sold for laboratory and scientific research purposes only. It is not approved for human consumption, medical use, or veterinary use. The information presented here does not constitute medical advice, a recommendation for self-administration, or an endorsement of off-label use. Researchers are responsible for complying with all applicable laws, regulations, and institutional guidelines regarding the use of this compound. For more information, please see the Research Disclaimer.
Reviewed by the Volta Peptides Research Team